Drugs / GM608
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01850381 | Jun 2013 → Jul 2014 | Parkinson disease | Genervon Biopharmaceuticals, LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01850381 ↗ |
| Action | Restore | “This pilot trial is designed to test proof of principle, i.e. determine if a 2-week treatment with this agent can restore the nonfunctioning nigral dopaminergic neurons in PD...” NCT01850381 ↗ |
| Modality | Peptide | “The investigational drug GM608 is a synthetic oligopeptide containing 6 amino acids” NCT01850381 ↗ |
| Route | Intravenous | “Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min” NCT01850381 ↗ |